中文
| Catalogue |
| Recommend Products |
Company News
- AMSBIO: Embedded Chondroitinase ABC Shows Promise for Spinal Injury Treatment 1/8/2019
- AMSBIO Expands Wnt Signaling Pathway Product Portfolio 12/12/2018
- AMSBIO: High Yield Cell-Free Protein Expression Kit 11/30/2018
- AMSBIO: Induced Pluripotent Stem Cells for Regenerative Research 11/20/2018
- AMSBIO: Consistent High Quality Cell Line Controls 11/3/2018
- AMSBIO: Activator Cell Line for Immune Checkpoint Therapy Research 10/12/2018
- AMSBIO ScreenIn3D Innovation Draws Accolades 10/8/2018
- AMSBIO: Circulating Tumor DNA Reference Standards 9/19/2018
- AMSBIO: Engineering Immune Cells to Treat Cancers 8/24/2018
- AMSBIO: Flexible & Precise Control of Gene Expression 8/17/2018
- AMSBIO: Exosome Isolation Manufacturing & Characterization 7/24/2018
- AMSBIO: Powerful CRISPR/Cas9 Gene Editing Kits 7/19/2018
- AMSBIO Launch New Screening Company 7/5/2018
- AMSBIO: 3D-iPSC Matrix Enables More Accurate In Vivo Predictions 6/21/2018
- AMSBIO: Cell Culture Medium for Clinical Research 6/5/2018
- AMSBIO: High Throughput Gene Expression Analysis Service 5/15/2018
- AMSBIO: Isogenic Cell Lines for Cancer Research 5/3/2018
- AMSBIO: Sustained Episomal Gene Expression Free from Foreign DNA 4/18/2018
- AMSBIO : Comprehensive Toolkit for Exosome Research 3/29/2018
- AMSBIO Signs Global Agreement for Groundbreaking Myotube Technology 3/23/2018